NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00152217,Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC),https://clinicaltrials.gov/study/NCT00152217,,COMPLETED,"This controlled study is designed to evaluate the efficacy of TS-1 on survival compared with surgery alone. Patients will be randomly assigned to receive either surgery alone or surgery followed by treatment with TS-1 within 45 days after curative resection (curability A or B). To assess the efficacy, data on recurrence and survival will be collected from the time of enrollment until 5 years after surgery. To evaluate safety, data on adverse events will be collected from the time of enrollment until 1 year after surgery.",NO,Gastric Cancer,DRUG: TS-1 (S-1)|PROCEDURE: Surgery,"Overall survival, every course for first three courses, then every other course","Relapse-free survival, adverse events, any time",,"Taiho Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",91023038,2001-09,2007-05,2010-12,2005-09-09,,2011-07-07,"National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan",
